Anavex Life Sciences Corp. (NASDAQ:AVXL) & Windtree Therapeutics (WINT) Financial Review

Windtree Therapeutics (NASDAQ: WINT) and Anavex Life Sciences Corp. (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Earnings & Valuation

This table compares Windtree Therapeutics and Anavex Life Sciences Corp.’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.19 million 0.82 -$31.78 million ($5.25) -0.04
Anavex Life Sciences Corp. N/A N/A -$15.61 million ($0.39) -9.21

Anavex Life Sciences Corp. has higher revenue, but lower earnings than Windtree Therapeutics. Anavex Life Sciences Corp. is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Windtree Therapeutics and Anavex Life Sciences Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -3,983.56% N/A -326.94%
Anavex Life Sciences Corp. N/A -95.68% -84.88%

Insider & Institutional Ownership

36.8% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 22.9% of Anavex Life Sciences Corp. shares are owned by institutional investors. 1.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 11.6% of Anavex Life Sciences Corp. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Windtree Therapeutics and Anavex Life Sciences Corp., as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 1 0 2.50
Anavex Life Sciences Corp. 0 0 3 0 3.00

Windtree Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 4,110.53%. Anavex Life Sciences Corp. has a consensus target price of $13.67, indicating a potential upside of 280.69%. Given Windtree Therapeutics’ higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than Anavex Life Sciences Corp..

Volatility & Risk

Windtree Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Anavex Life Sciences Corp. has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.

Summary

Anavex Life Sciences Corp. beats Windtree Therapeutics on 7 of the 12 factors compared between the two stocks.

About Windtree Therapeutics

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply